Brokers Issue Forecasts for XENE Q1 Earnings

Key Points

• HC Wainwright forecasts a Q1 2027 loss of $1.21 per share for Xenon Pharmaceuticals, compared with a full-year consensus loss estimate of $4.92 per share.
• Xenon’s latest quarterly loss of $1.11 per share beat analyst expectations of $1.16, although it was wider than the $1.07 loss reported a year earlier.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a consensus price target of $77.13 versus the stock’s reported price of $63.36; investors are also focused on the expected azetukalner NDA filing.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - HC Wainwright issued their Q1 2027 earnings estimates for Xenon Pharmaceuticals in a report released on Friday, August 7th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of ($1.21) for the quarter. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($4.92) per share.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.05. During the same quarter in the previous year, the business earned ($1.07) EPS.

Several other analysts also recently weighed in on XENE. Needham & Company LLC dropped their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Friday, May 8th. Wells Fargo & Company reiterated an "overweight" rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, August 1st. Royal Bank Of Canada reduced their price target on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating for the company in a research report on Friday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $77.13.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock opened at $63.36 on Monday. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of -13.37 and a beta of 0.62. The business has a fifty day moving average of $60.24 and a 200 day moving average of $54.30. Xenon Pharmaceuticals has a 1 year low of $32.78 and a 1 year high of $72.66.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the company's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gillian Cannon sold 1,190 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. The trade was a 44.99% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several large investors have recently made changes to their positions in XENE. BlackRock Inc. acquired a new stake in Xenon Pharmaceuticals during the second quarter valued at $454,057,000. Avoro Capital Advisors LLC grew its position in shares of Xenon Pharmaceuticals by 0.5% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company's stock valued at $243,124,000 after acquiring an additional 24,444 shares during the period. Janus Henderson Group PLC increased its stake in shares of Xenon Pharmaceuticals by 2.3% in the 1st quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company's stock valued at $242,858,000 after purchasing an additional 91,948 shares in the last quarter. Wellington Management Group LLP raised its holdings in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company's stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the period. Finally, Capital International Investors raised its holdings in Xenon Pharmaceuticals by 7.3% in the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company's stock worth $153,058,000 after purchasing an additional 233,466 shares during the period. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Azetukalner NDA filing remains on track: Following an FDA meeting, RBC said Xenon still expects to submit a New Drug Application for azetukalner later this quarter. The filing is a major near-term catalyst for the company’s lead product candidate. Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
• Positive Sentiment: Quarterly loss beat expectations: Xenon reported a second-quarter adjusted loss of $1.11 per share, narrower than analysts’ expected $1.16 loss. Management also said its cash position should fund operations into 2029, reducing immediate financing and dilution concerns. XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
• Neutral Sentiment: Pipeline remains the investment focus: Xenon has no reported product sales, so valuation depends largely on azetukalner’s clinical and regulatory progress. The company’s earnings call emphasized development plans and the anticipated NDA submission rather than near-term commercial revenue. Xenon Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Losses continue to widen year over year: Although the quarterly loss beat estimates, the reported per-share loss was worse than the $1.07 loss recorded in the same period last year. With sales still nil and the company continuing to fund research and development, investors remain sensitive to execution and regulatory risks. Xenon Pharmaceuticals Q2 Loss Widens

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source